24/7 Market News Snapshot 29 September, 2025 – Dogwood Therapeutics, Inc. Common Stock (NASDAQ:DWTX)

September 29, 2025

DENVER, Colo., 29 September, 2025 (www.247marketnews.com) – (NASDAQ:DWTX) are discussed in this article.
Dogwood Therapeutics, Inc. (DWTX) is experiencing a notable surge, currently trading at $7.324, reflecting a remarkable 32.68% increase from the previous close of $5.520. The pre-market session has witnessed a robust trading volume of 1.54 million shares, buoyed by positive investor sentiment following recent developments. Market dynamics suggest a favorable trend for DWTX as it captures attention in the sector, positioning itself as a leading innovator.

In conjunction with this market response, Dogwood Therapeutics has made a strategic advancement by acquiring a royalty-free, global license to develop Serpin Pharma’s intravenous formulation of SP16. This first-in-class LRP1 agonist represents a pioneering approach to address chemotherapy-induced peripheral neuropathy (CIPN), a prevalent and painful condition affecting many cancer patients. The upcoming Phase 1b study of SP16, fully funded by the National Cancer Institute, underscores the high expectations surrounding its efficacy in managing CIPN symptoms.

Greg Duncan, CEO of Dogwood Therapeutics, emphasized the strategic value of this acquisition, stating, “With the in-licensing of SP16, we’re strengthening our capabilities to deliver tailored solutions for pain and neuropathy management.” This partnership not only aligns with the company’s mission but also conserves existing capital for further clinical developments.

Additionally, Dogwood’s lead candidate, Halneuron®, a NaV1.7-specific sodium channel inhibitor, is currently progressing through a Phase 2b trial, showcasing significant potential in alleviating cancer-related pain. The complementary nature of SP16 with Halneuron® is anticipated to enhance patient care, making strides in cancer symptom management.

With a commitment to developing transformative treatments, Dogwood Therapeutics is aiming to provide effective solutions for the challenges faced by patients dealing with pain and neuropathy, promising significant advancements in patient outcomes.

Related news for (DWTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.